• 제목/요약/키워드: Gastrointestinal cow milk allergy

검색결과 8건 처리시간 0.02초

새로운 분류법에 따른 소아 위장관 우유 알레르기 질환에 관한 임상적 고찰 (Clinical Observations of Gastrointestinal Cow Milk Allergy in Children According to a New Classification)

  • 황진복;최선윤;권태찬;오훈규;감신
    • Pediatric Gastroenterology, Hepatology & Nutrition
    • /
    • 제7권1호
    • /
    • pp.40-47
    • /
    • 2004
  • 목 적: 효율적인 진단과 치료 및 적절한 의학적 교류를 목적으로 소아 위장관 알레르기 질환의 새로운 분류법이 발표되었다(J Pediatr Gastroenterol Nutr 2000;30:S87-94). 그러나 명칭과 분류의 변경으로 이미 알려진 질환들이 새로운 질환으로 보고되기도 하는데, 저자들은 새로운 분류법에 따른 소아 위장관 알레르기 질환의 질병군에 관하여 알아보고, 국내에서 이미 보고된 관련 문헌을 함께 고찰하여 의학적 교류에 혼선을 최소화 하고자 한다. 방 법: 2003년 3월부터 7월까지 계명대학교 의과대학 소아과를 방문하여, 우유 유발 및 제거시험, 내시경을 이용한 조직생검 등을 이용하여 소아 GI-CMA로 진단된 37례(남 19, 여 18)를 대상으로 후향성 조사하였다. 새로운 분류에는 포함되지 않았으나 위식도역류 관련 알레르기를 추가하였다. 국내 문헌은 소아과학회지, 소아소화기영양학회지, 소아알레르기호흡기학회지를 근거로 고찰하였다. 결 과: 1) 대상 환아의 연령은 2주~15개월, 평균 $5.4{\pm}4.8$개월이었다. 2) 출생체중은 전례에서 10~90백분위수를 차지하였으며, 25~75백분위수가 25례(68%)를 차지하였다. 내원 당시 체중은 3백분위수 이하가 18례(49%)이었다. 3) 증상발현에서 진단까지 걸린 시간은 2주~12개월, 평균 $2.4{\pm}3.3$개월이었다. 4) IgE 군인 IgE 매개형 우유알레르기(IGE) 6례(16%), IgE와 Non-IgE 혼합군인 호산구성 위장관염(EOS) 2례(5%), Non-IgE군인 전형적 우유 단백질 유발 장관염(CMPIE-T) 7례(19%), 비전형적 우유 단백질 유발 장관염(CMPIE-AT) 5례(14%), 알레르기성 대장염(AC) 12례(32%)이었다. 위식도역류증 관련 우유 알레르기(GERA)는 5례(14%)이었다. CMPIE-T 전례에서 소장 조직생검상 장병증이 관찰되었다. 5) 진단 당시 연령은 IGE $4.3{\pm}0.8$개월, EOS 생후 2주와 14개월, CMPIE-T $3.8{\pm}4.6$개월, CMPIE-AT $10.4{\pm}3.8$개월, AC $3.4{\pm}3.9$개월, GERA $7.8{\pm}5.7$개월로 질환군간 유의한 차이를 보였다(p<0.05). 6) 내원 당시 3백분위수 이하를 보인 경우가 IGE 17%, EOS 0%, CMPIE-T 86%, CMPIE-AT 60%, AC 25%, GERA 100%로 질환군간 유의한 차이를 보였다(p<0.05). 7) 국내 문헌을 고찰하여 소아 위장관 우유 알레르기 질환은 만성설사, 난치성설사, 우유 불내성, 우유 알레르기, 위장관 알레르기, 우유 과민성 장병증, 호산구성 위장관염, 알레르기성 대장염 등의 용어로 보고되었다. 결 론: 새로운 분류법에 따른 소아 위장관 우유 알레르기 질환은 연령, 임상 증상, 위장관 침범 부위에 따라 특징적인 유형으로 구분할 수 있으며, 임상적으로 드물지 않다. 국내의 문헌을 통하여 다양한 용어로 각 유형의 알레르기 질환들은 연구 보고되어 왔다.

  • PDF

Retrospective and Prospective Determination of the Cow's Milk-Related Symptom Score (CoMiSSTM) Values in Symptomatic Infants

  • Kozlowska-Jalowska, Anna;Horvath, Andrea;Vandenplas, Yvan;Szajewska, Hania
    • Pediatric Gastroenterology, Hepatology & Nutrition
    • /
    • 제24권4호
    • /
    • pp.384-391
    • /
    • 2021
  • Purpose: The Cow's Milk-related Symptom Score (CoMiSSTM) was developed as an awareness tool for evaluating cow's milk-related symptoms in otherwise healthy children. Using a convenience sample of participants, this cross-sectional study aimed to determine CoMiSSTM values of symptomatic infants based on retrospectively or prospectively obtained information. Methods: CoMiSSTM values were determined in infants aged <12 months with symptoms suggestive of cow's milk protein allergy or functional gastrointestinal disorders. The exclusion criteria were previous diagnosis with acute or chronic disease, treatment with a therapeutic formula, and in case of breastfeeding, an elimination diet followed by the mother. Two CoMiSSTM values were assessed. A retrospective collection was defined as the collection of data after initial contact with the medical center but before the first medical consultation. A prospective collection was defined as the collection of data within 24 hours from the time of medical consultation but before starting any therapeutic intervention. The CoMiSSTM total and individual component scores obtained retrospectively or prospectively were compared between groups using the Wilcoxon signed-rank test. Results: This study was performed between August and November 2019. Data of 110 children (62 males and 48 females), with a mean±standard deviation age of 18.2±11.7 weeks, were obtained. The total CoMiSSTM value (p<0.001) and some individual component scores (crying, regurgitation, and stool) were significantly lower when collected prospectively than when collected retrospectively. Conclusion: CoMiSSTM values were retrospectively and prospectively determined. Lower CoMiSSTM values were obtained during prospective evaluation. Possible differences should be considered when using CoMiSSTM in clinical practice.

Is This Symptom Even a Food Allergy?: Clinical Types of Food Protein-induced Enterocolitis Syndrome

  • Hwang, Jin-Bok
    • Pediatric Gastroenterology, Hepatology & Nutrition
    • /
    • 제17권2호
    • /
    • pp.74-79
    • /
    • 2014
  • Food protein-induced enterocolitis syndrome (FPIES) is an under-recognized non-IgE-mediated gastrointestinal food allergy. The diagnosis of FPIES is based on clinical history, sequential symptoms and the timing, after excluding other possible causes. It is definitively diagnosed by an oral food challenge test. Unfortunately, the diagnosis of FPIES is frequently delayed because of non-specific symptoms and insufficient definitive diagnostic biomarkers. FPIES is not well recognized by clinicians; the affected infants are often mismanaged as having viral gastroenteritis, food poisoning, sepsis, or a surgical disease. Familiarity with the clinical features of FPIES and awareness of the indexes of suspicion for FPIES are important to diagnose FPIES. Understanding the recently defined clinical terms and types of FPIES is mandatory to suspect and correctly diagnose FPIES. The aim of this review is to provide a case-driven presentation as a guide of how to recognize the clinical features of FPIES to improve diagnosis and management of patients with FPIES.

Middle East Consensus Statement on the Diagnosis and Management of Functional Gastrointestinal Disorders in <12 Months Old Infants

  • Vandenplas, Yvan;Alturaiki, Muath Abdurrahman;Al-Qabandi, Wafaa;AlRefae, Fawaz;Bassil, Ziad;Eid, Bassam;El Beleidy, Ahmed;Almehaidib, Ali Ibrahim;Mouawad, Pierre;Sokhn, Maroun
    • Pediatric Gastroenterology, Hepatology & Nutrition
    • /
    • 제19권3호
    • /
    • pp.153-161
    • /
    • 2016
  • This paper covers algorithms for the management of regurgitation, constipation and infantile colic in infants. Anti-regurgitation formula may be considered in infants with troublesome regurgitation, while diagnostic investigations or drug therapy are not indicated in the absence of warning signs. Although probiotics have shown some positive evidence for the management of functional gastrointestinal disorders (FGIDs), the evidence is not strong enough to make a recommendation. A partially hydrolyzed infant formula with prebiotics and ${\beta}$-palmitate may be considered as a dietary intervention for functional constipation in formula fed infants. Lactulose has been shown to be effective and safe in infants younger than 6 months that are constipated. Macrogol (polyethylene glycol, PEG) is not approved for use in infants less than 6 months of age. However, PEG is preferred over lactulose in infants >6 months of age. Limited data suggests that infant formula with a partial hydrolysate, galacto-oligosaccharides/fructo-oligosaccharides, added ${\beta}$-palmitate may be of benefit in reducing infantile colic in formula fed infants in cases where cow's milk protein allergy (CMPA) is not suspected. Evidence suggests that the use of extensively hydrolyzed infant formula for a formula-fed baby and a cow's milk free diet for a breastfeeding mother may be beneficial to decrease infantile colic if CMPA is suspected. None of the FGIDs is a reason to stop breastfeeding.

A partially hydrolyzed whey formula provides adequate nutrition in high-risk infants for allergy

  • Yang, Jiyeon;Yang, Song I;Jeong, Kyunguk;Kim, Kyung Won;Kim, Yoon Hee;Min, Taek Ki;Pyun, Bok Yang;Lee, Jeongmin;Jung, Ji A;Kim, Jeong Hee;Lee, Sooyoung
    • Nutrition Research and Practice
    • /
    • 제16권3호
    • /
    • pp.344-353
    • /
    • 2022
  • BACKGROUND/OBJECTIVES: Hydrolyzed formula is often fed to infants with gastrointestinal or immune issues, such as malabsorption or cow's milk allergy, because enzymatic treatment has rendered it more digestible and less allergenic than standard cow's milk formula (SF). Partially hydrolyzed formula (PHF) should be considered for those infants who are intolerant to extensively hydrolyzed formula. However, there are concerns about the nutritional insufficiencies of PHF. We aimed to evaluate the effects of PHF on the growth and health indicators in infants who were at high-risk of allergic disease and potential candidates for consuming PHF. SUBJECTS/METHODS: A total of 83 infants aged 0-2 mon with a family history of allergies were assigned to consume either PHF or SF until 24 weeks of age. Anthropometric measures were obtained at baseline, 12 weeks, and 24 weeks; blood samples were drawn and evaluated at the end of the study. RESULTS: No significant differences were observed in weight, height, and weight-for-height at any time point in each sex between the PHF and SF groups. At 24 weeks of age, the weight-for-age and height-for-age z-scores of the SF group were higher than those of the PHF group, but there was no significant difference in the weight-for-height z-score. There were no significant differences in levels of white blood cells, hemoglobin, ferritin, protein, albumin, aspartate aminotransferase, alanine aminotransferase, eosinophil cationic protein, and immunoglobulin E. CONCLUSIONS: In this study, there were no differences in growth and blood panels between the infants consuming PHF or SF. Therefore, infants who are unable to tolerate SF can be fed PHF without nutritional concerns about growth.

위장관 증세 위주로 발현하는 영유아기 우유 알레르기 질환의 3가지 임상 유형에 관한 고찰 (The Three Types of Clinical Manifestation of Cow's Milk Allergy with Predominantly Intestinal Symptoms)

  • 이정진;이은주;김현희;최은진;황진복;한창호;정혜리;권영대;김용진
    • Pediatric Gastroenterology, Hepatology & Nutrition
    • /
    • 제3권1호
    • /
    • pp.30-40
    • /
    • 2000
  • 목 적: 위장관 증세 위주로 발현하는 우유 알레르기(cow's milk allergy with predominantly gastrointestinal symptoms, CMA-GI)는 유발시험 후 유해반응의 발현시간이 즉각적이지 않아 병력청취를 통하여 우유와 발현 증상의 관련성을 의심하기가 쉽지 않다. 또한, 가벼운 구토, 설사 증상부터 괴사성 장염의 발병처럼 높은 사망률을 보이는 경우까지 임상적 스팩트럼이 다양하며, 감염성 질환 등 타 질환과의 철저한 감별진단이 요구되나 어려운 경우가 많다. 저자들은 CMA-GI를 3가지 임상유형으로 분류하여 진단적 효용성을 높이고, 효율적인 치료계획 수립에 도움을 주고자 본 연구를 시행하였다. 대상 및 방법: 1995년 3월부터 1997년 6월까지 대구효성가톨릭대학병원 소아과에 급, 만성 설사 등 위장관 증세를 주소로 내원하여 우유제거 및 유발시험의 반응을 근거로 CMA-GI로 진단된 30명(남 22명, 여 8명)의 영유아를 대상으로 우유 유발시험에 따른 유해반응의 발현시기 및 양상에 따라 3가지 임상 유형으로 분류하고, 입원당시 임상소견, 유해반응의 양상, 면역학적 검사소견, 소장 생검조직의 형태학적 분석 등을 이용하여 각 유형을 비교 관찰하였다. Quick (Q)형은 우유 유발시험 후 1시간 이내에 두드러기형 발진 등이 발현한 경우로, Slow (S)형은 유해반응이 1시간에서 24시간사이에 발현한 경우로, Quick & Slow (Q&S)형은 Q형과 S형의 증상이 함께 나타나는 경우로 분류하였다. 결 과: 1) 대상환아 30명 중 Q형 5례, S형 20례, Q&S형 5례로, S형의 환아가 가장 많았다. 2) 입원당시 연령은 Q형 $81.4{\pm}67.1$일, S형 $31.9{\pm}12.7$일, Q&S형 $366.0{\pm}65.0$일로 각 유형에 따라 호발 연령의 차이를 보였다(p<0.05). 입원당시 체중은 Q형 10~50백분위수, S형 10백분위수 이하, Q&S형 10~25백분위수로 S형과 다른 유형간에 차이를 보였으며(p<0.05), S형 환아 중 90%에서 3백 분위수 이하로 관찰되었다. 3) 입원당시 말초혈액검사상 백혈구수는 Q형 $5,700{\sim}12,300/mm^3$, S형 $10,000{\sim}33,400/mm^3$, Q&S형 $5,200{\sim}14,900/mm^3$로 S형과 다른 유형간에 차이를 보였다(p<0.05). 입원당시 혈중 알부민치는 Q형 $4.2{\pm}0.4\;g/dl$, S형 $3.0{\pm}0.3\;g/dl$, Q&S형 $4.0{\pm}0.3\;g/dl$로 S형과 다른 유형간에 차이를 보였으며(p<0.05), S형 환아 중 85%에서 혈중 알부민치가 3.5 g/dl 이하였다. 4) 소장 조직생검의 형태학적 분석에서 융모의 높이는 Q형, Q&S형은 정상 대조군과 유의한 차이를 보이지 않았으나, S형에서는 의미있는 감소를 보였으며(p<0.05), 45%에서 아전 융모위축(subtotal villous atrophy), 55%에서 부분(partial) 융모위축의 소견이 보여 전례에서 장병증(enteropathy) 소견이 관찰되었다. 5) 추적 관찰 중 타 음식물에 대한 알레르기의 발현은 S형의 환아군에서는 환아의 연령, 전신 상태의 불안정과 위험성 등 윤리적 측면을 고려하여 유발시험을 시행하지 않았으며, Q형에서도 환아의 연령을 고려하여 다양한 유발시험은 제한하였으나, 대개 우유, 대두유, 이유식 분유, 계란 등 1~2가지의 음식물에 유해 반응을 보이는 것으로 관찰되었다. Q&S형군에서는 연령에 따른 이유 식이의 필요성에 따라 다양한 유발시험을 시행하였으며, 계란, 감자, 새우 등 해산물, 두부, 사과, 당근, 쇠고기, 닭고기 등 환자에 따라 다양한 음식물에 유해반응을 보이는 것으로 관찰되었다. 6) 입원당시 혈중 IgE치, 호산구수, 우유단백 RAST치, 콩단백 RAST치, 피부반응검사는 유형간에 차이를 보이지 않았다. 결 론: 위장관 증세 위주로 발현하는 우유 알레르기는 유발 시험에 따른 유해 반응의 발현 시기 및 양상에 따라 3가지 유형으로 분류될 수 있으며, 이들의 임상소견, 소장생검조직 소견, 면역학적 검사 소견, 타 음식물에 대한 알레르기 발현 유무 등에서 각 유형별로 특징적인 임상 양상을 관찰할 수 있으며, 이들 소견을 비교, 분석하여 감별 진단하는 것이 CMA-GI의 진단 및 치료적 접근에서 효용성이 높을 것으로 판단된다.

  • PDF

식품 단백질 유발성 장염 증후군: 임상적 접근과 병태생리의 최신 지견 (Food Protein-induced Enterocolitis Syndrome: an Update on Clinical Approaches and Its Pathophysiology)

  • 황진복
    • Pediatric Gastroenterology, Hepatology & Nutrition
    • /
    • 제10권2호
    • /
    • pp.117-128
    • /
    • 2007
  • Food protein-induced enterocolitis syndrome (FPIES) is a non-IgE mediated hypersensitivity disorder, which is associated with mainly gastrointestinal symptoms and has a delayed onset. The vomiting and/or diarrheal symptoms of FPIES typically begin in the first month of life in association with a failure to thrive, metabolic acidosis, and shock. Therefore, the differential diagnosis of FPIES and neonatal or infantile sepsis-like illnesses or gastroenteritis is difficult. The early recognition of indexes of suspicion for FPIES may help in the diagnosis and treatment of this disorder. The diagnosis of FPIES is generally made through clinical practice and food-specific IgE test findings are typically negative in this condition. Therefore, oral cow's milk challenge (OCC) remains the valid diagnostic standard for FPIES. An investigation of positive OCC outcomes helps to find out a diagnostic algorithm of criteria of a positive challenge in FPIES. Moreover, it has not been clearly determined in infantile FPIES when $1^{st}$ follow up-oral food challenge (FU-OFC) should be performed, with what kind of food protein (e.g., cow's milk, soy), and how much protein should be administered. Hence, to prevent the risk of inappropriate FU-OFC or accidental exposure and achieve appropriate dietary management, it is necessary to identify tolerance rates to major foods under the careful follow up of infantile FPIES patients. On the other hand, small intestinal enteropathy with villous atrophy is observed in FPIES and this enteropathy seems to be in part induced by both of epithelial apoptosis and intercellular junctional complex breakdown. The purpose of this report is to introduce an update on diagnostic and therapeutic approaches in FPIES and suggest the possible histopathological evidences in this disorder.

  • PDF

Laxative Choice and Treatment Outcomes in Childhood Constipation: Clinical Data in a Longitudinal Retrospective Study

  • Chanpong, Atchariya;Osatakul, Seksit
    • Pediatric Gastroenterology, Hepatology & Nutrition
    • /
    • 제21권2호
    • /
    • pp.101-110
    • /
    • 2018
  • Purpose: Functional constipation (FC) is a common gastrointestinal (GI) problem affecting children's well-being and quality of life. Although polyethylene glycol (PEG) is recommended as the first line therapy, it is not always applicable in lower socioeconomic populations. Hence, this study aimed to compare clinical courses of FC in children treated with different medications in order to identify prognostic factors related to treatment outcomes. Methods: We reviewed the medical records of patients aged ${\leq}15$ years diagnosed with FC according to the Rome IV criteria from 2007 to 2015 at the GI clinic, Songklanagarind Hospital. Baseline characteristic, medical history, and treatment outcomes were collected at first and subsequent visits. Results: Exactly104 patients (median age at diagnosis, 2.8 years) were diagnosed with FC. The number of follow-up visits per patient ranged from 1 to 35. The median duration of follow-up was 18.0 months (range, 6.0-84.2 months). PEG was given to 21% of patients. During the follow up period, 76% of patients experienced first recovery with a median time to recovery of 9.8 months. There were no significant differences in time until first recovery and relapse between patients who received and those who did not receive PEG (p=0.99 and 0.06, respectively). Age >6 years, normal defecation frequency, no history of cow's milk protein allergy, and use of laxatives were associated with successful outcomes. Conclusion: Treatment outcomes between patients who had and never had PEG demonstrated no significant difference in our study. Hence, current practices in laxative prescriptive patterns may be effective.